Ventria Bioscience
Ventria Bioscience is a privately held biopharmaceutical company that uses its ExpressTec plant-based platform to produce recombinant proteins for medicine and biotechnology companies, replacing traditional bioreactors with rice-plant expression systems.
- Company typePrivate
- Founded1993
- HeadquartersJunction City, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Ventria Bioscience firmographics
Firmographics- Name
- Ventria Bioscience
- Legal name
- Ventria Bioscience Inc.
- Website
- https://ventria.com
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ventria Bioscience is a privately held biopharmaceutical company that uses its ExpressTec plant-based platform to produce recombinant proteins for medicine and biotechnology companies, replacing traditional bioreactors with rice-plant expression systems.
- Ownership category
- akta.pro rank
Ventria Bioscience industry classification
Industry- Product category
- Biopharmaceutical Manufacturing
- akta.pro primary industry
- Upstream Bioprocessing Systems & Equipment (cell culture/fermentation, bioreactors, feeds/media) (HLAAAJAA)
Keywords
Where Ventria Bioscience is headquartered
LocationHeadquarters
- HQ city
- Junction City
- HQ country
- United States
- HQ region
- North America
Markets served
Ventria Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure
Revenue model
- Recombinant Protein Products: Sale of recombinant proteins produced via the ExpressTec plant-based platform to medicine and biotechnology companies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Ventria Bioscience product offering
Product offeringCore offering
Ventria Bioscience develops and operates the ExpressTec platform, a plant-based recombinant protein production system that uses rice plants as natural bioreactors. The platform harnesses sunlight, soil, water, and air to manufacture recombinant proteins (including monoclonal antibodies, fusion proteins, enzymes, and multi-subunit molecules) that concentrate in rice-seed endosperm for harvest and purification, supplying medicine and biotechnology companies as an alternative to bacterial, yeast, and mammalian cell-culture expression systems.
Differentiator
Problem solved
Functional benefit
Products and services
- ExpressTec Recombinant Proteins A recombinant protein production service that uses rice plants as natural bioreactors, producing monoclonal antibodies, fusion proteins, enzymes, and multi-subunit molecules in a contamination-free eukaryotic host system for medicine and biotechnology companies needing commercial-scale yields at lower cost than traditional cell-culture systems.
Companies that use Ventria Bioscience
Customer profileSegments1 record
Ideal customer profiles1 record
Ventria Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Ventria Bioscience competitors and assessment
Company assessmentDirect peers
- Protalix BioTherapeutics: Plant cell-based biopharmaceutical developer using its ProCellEx platform to produce therapeutic proteins. Directly comparable to Ventria as a plant-based alternative to mammalian cell-culture expression systems targeting biologics manufacturing.
- iBio: Plant-based biologics company using its FastPharming system in hydroponically grown Nicotiana benthamiana. Comparable to Ventria as a plant-based upstream bioprocessing platform producing recombinant proteins and antibodies.
- Kentucky BioProcessing (KBP): Operates a tobacco-plant-based protein expression and biomanufacturing platform for therapeutics and vaccines. Directly comparable to Ventria's plant-based bioreactor approach for recombinant protein production.
- Medicago: Developed plant-based (tobacco-related) Virus-Like Particle (VLP) technology for vaccine and antibody production. A close functional peer in plant-based recombinant biologics manufacturing before its wind-down/acquisition activity.
Emerging players
- PlantForm Corporation: Uses a vivoXPRESS plant-based platform to produce therapeutic proteins and monoclonal antibodies in plants. An emerging direct competitor in plant-made pharmaceuticals with similar target customers as Ventria.
- Leaf Expression Systems: UK-based developer of the Hypertrans plant-based transient expression system for producing vaccines, antibodies, and complex proteins. An emerging peer in upstream plant-based bioprocessing for research and clinical use.
- Cape Bio Pharms: South African plant-based expression company producing reagents, antibodies, and enzymes using a plant platform. Comparable to Ventria as a smaller-scale plant-based protein manufacturer focused on contamination-free and cost-effective production.
Broad incumbents
- Lonza Biologics: Global CDMO with large-scale mammalian and microbial biologics manufacturing capacity. A broad incumbent comparator that defines the incumbent expression paradigm (especially mammalian cell culture) against which Ventria's plant-based platform competes.
- Samsung Biologics: Large-scale biopharmaceutical CDMO offering mammalian cell-culture-based contract manufacturing services. Relevant broad incumbent peer representing the scale and cost benchmark Ventria must compete against.
- Catalent: Major biologics CDMO with broad mammalian and microbial expression capabilities serving global biopharma. Comparable as a broad incumbent supplier against which plant-based platforms like ExpressTec position their cost and contamination advantages.
Market position
Customer concentration
Ventria Bioscience social profiles
Digital presenceVentria Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ventria Bioscience leadership team
Management profileNumber of profiles
Profiles3 records
Ventria Bioscience funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ventria Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ventria Bioscience
What does Ventria Bioscience do?
Ventria Bioscience develops and operates the ExpressTec platform, a plant-based recombinant protein production system that uses rice plants as natural bioreactors. The platform harnesses sunlight, soil, water, and air to manufacture recombinant proteins (including monoclonal antibodies, fusion proteins, enzymes, and multi-subunit molecules) that concentrate in rice-seed endosperm for harvest and purification, supplying medicine and biotechnology companies as an alternative to bacterial, yeast, and mammalian cell-culture expression systems.
Is Ventria Bioscience a public or private company?
Ventria Bioscience is a private company. It is classified as unknown and is currently operating.
When was Ventria Bioscience founded?
Ventria Bioscience was founded in 1993. It employs 11 to 50 people.
Where is Ventria Bioscience based?
Ventria Bioscience is headquartered in Junction City, United States, in the North America region.
How does Ventria Bioscience make money?
One revenue line is on record: recombinant Protein Products.
Who are Ventria Bioscience's main competitors?
Direct peers on record are Protalix BioTherapeutics, iBio, Kentucky BioProcessing (KBP) and Medicago. Emerging players are PlantForm Corporation, Leaf Expression Systems and Cape Bio Pharms. Broad incumbents are Lonza Biologics, Samsung Biologics and Catalent.
Does Ventria Bioscience have an API?
No public API is recorded for Ventria Bioscience.
What industry is Ventria Bioscience in?
Ventria Bioscience's product category is Biopharmaceutical Manufacturing. Its primary akta.pro industry code is HLAAAJAA, Upstream Bioprocessing Systems & Equipment (cell culture/fermentation, bioreactors, feeds/media).